Clinical Trial Update: A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update evaluating AK154 as monotherapy or in combination with AK104/AK112, followed by sequential mFOLFIRINOX, in surgically resected pan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• AK104 (PD-1/CTLA-4 bispecific antibody)
• AK112
• AK154
• mFOLFIRINOX

Snippet

Sponsor: Akeso | Conditions: Pancreas Cancer, Pancreas Cancer, Duct Cell Adenocarcinoma | Phase 1 | Status: NOT_YET_RECRUITING